• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
    • investors & partners
  • approach
  • pipeline
    • CGS-200-5
    • PRL-02
  • news & insights
    • news
    • presentations
    • press releases
    • references (CGS-200-5)
    • references (PRL-02)
  • contact
  • Menu
  • our constellation

    Our current pipeline encompasses brilliant new products that offer promise for highly unmet needs.

CGS-200-5

There are currently no approved therapies that effectively manage moderate to severe OA pain without significant concerns related to tolerability, safety, or addiction potential.  Topical CGS-200-5 (5% capsaicin) has clinically been shown to significantly reduce OA knee pain.  In a Phase 2 study, CGS-200-5 reduced pain by 50% (based on WOMAC pain score) while demonstrating good safety and tolerability. CGS-200-5 also demonstrated highly durable pain relief.  Patients on average reported diminished pain through 90 days, the final time point of the Phase 2 study, following just four consecutive days of topical treatment at study start.  Acknowledging the therapeutic potential of topical high-concentration capsaicin, the American College of Rheumatology recently revised its OA treatment guideline to conditionally recommend topical capsaicin for knee OA pain.

The FDA recently confirmed a Phase 2b/3 pivotal study design as well as the eligibility of CGS-200-5 for the highly efficient 505 (b) (2) regulatory approval process.  We anticipate filing a New Drug Application (NDA) for the product in 2024, with the potential for market clearance as early as 2025.

A topical product that can provide safe, effective and durable pain relief for OA patients has significant commercial potential.  A recently completed, independent market research study projected that peak year sales of CGS-200-5 in the U.S. in excess of $1.6 billion annually.

  • CGS-200-5
  • PRL-02
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • contact
© 2020-2021 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top